Anatara Lifesciences Ltd

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

     

News

Anatara Lifesciences Ltd (ASX:ANR) PAC Partners Equity Research Report

🕔5/17/2019 10:26:26 AM 890

In the lead up to World IBD Day, this coming Sunday, 19th May, PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Unite for World IBD Day and Crohn's and Colitis Awareness Month

🕔5/14/2019 10:40:51 AM 924

The month of May marks two very important days in the IBD calendar - Crohn's and Colitis Awareness Month, which takes place throughout May and World IBD Day, which is being held this Sunday, 19 May. Both events are designed to raise awareness for Crohn's disease and Ulcerative colitis, and show support to the 10 million people worldwide who live with IBD.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Finance News Network Interviews CEO Steven Lydeamore

🕔5/2/2019 4:54:08 PM 1476

While in Sydney last month, Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore sat down with Anna Napoli at Finance News Network, Australia's largest provider of online business and finance news.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Report

🕔4/30/2019 8:50:52 AM 920

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st March 2019. The Company's cash plus term deposits at the end of the quarter stood at $6.4m, incorporating receipt of the 2017-2018 $1.249m R&D tax refund which was received on 14th January 2019. On 31st March 2019, the Company had cash at bank of $1,395,664 and $5,050,000 in term deposits.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Pitt Street Research Interviews CEO Steven Lydeamore

🕔4/16/2019 10:53:59 AM 1605

While in Sydney earlier this month, Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore sat down with Stuart Roberts at Pitt Street Research, one of Australia's most experienced providers of equity research for ASX-listed small and mid cap companies.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Morgans Financial Limited Interviews CEO Steven Lydeamore

🕔3/29/2019 9:58:35 AM 1834

While in Brisbane this week, Anatara Lifesciences CEO Steve Lydeamore (ASX:ANR) sat down with Scott Power, Senior Analyst at Morgans Financial Limited, Australia's largest national full-service retail stockbroking and wealth management network.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Video Interview with CEO Steven Lydeamore on Development of Human Health Product

🕔3/22/2019 1:03:12 PM 4351

Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore, recently appointed to the company, is interviewed by ABN Newswire on the development of Irritable Bowl Syndrome (IBS) dietary supplements to address the growing need for a product that addresses the full range of IBS symptoms.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) PAC Partners Equity Research Report

🕔3/19/2019 9:29:24 AM 1832

PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Pitt Street Research Report

🕔3/19/2019 9:13:38 AM 1738

Pitt Street Research has released its latest initiating research and valuation report on Anatara Lifesciences (ASX:ANR). The report provides a $1.34 per share base case and a $3.61 optimistic case using a probability-weighted DCF valuation approach.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Half Yearly Report

🕔2/19/2019 8:21:30 AM 1875

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4D financial report for the half year ending 31st December 2018.

Read Full Article
###

0 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 499) (Last 30 Days: 1475) (Since Published: 34892) 

Markets ASX:ANR

Company Data

    Headquarters
  • 433 Logan Road, Stones Corner
    Brisbane, Queensland 4120
    Australia
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.anataralifesciences.com
  • E:
  • info@anataralifesciences.com

Company Reports

Presentations

Research Report

Quarterly Report

Social Media